Since April 2014, Mr. Fu has served as the chief executive officer and legal representative
at Shanghai Kangshiqiao Business Consulting Co., Ltd. in the PRC, a business consulting
and investment company.
From 2011 to 2013, Mr. Fu served as a manager of the investment department at Far
East Horizon Limited in the PRC, a financial service company whose shares are listed
on the Hong Kong Stock Exchange (stock code: HK.3360). From 2008 to 2010, Mr. Fu
served as a vice president at Standard Chartered China where he was mainly responsible
for private equity investment in relation to infrastructure project. From 2006 to
2008, Mr. Fu served as a business analyst at Macquarie Group China.
Mr. Fu received his bachelor’s degree in electrical and electronic engineering from
Nanyang Technological University in Singapore in February 2005.
Mrs..Wu has served as VP of our Group since January 2014.
Since joining our Group, Ms.Wu is primarily responsible for overseeing the daily
operations of our Group, including management of human resources, general affairs
and business administration of our Group.
She received her bachelor’s degree in Industry Design from Zhejiang University in
Dr.Wu has served as CEO and Director of our Group since founding Ascletis in April
Prior to founding Ascletis, Dr.Wu was Vice President of HIV Drug Discovery Performance
Unit at GlaxoSmithKline based in Research Triangle Park, North Carolina, USA, where
he was mainly responsible for discovery and development of multiple pre-clinical
and clinical stage drug candidates.
Before joining GlaxoSmithKline, he served as Vice President of Pre-clinical and Basic
Research at Ambrilia Biopharma in Montreal, Canada.
During his career, he also held senior management positions with increasing responsibilities
at PhageTech, Immunex and Novartis.
He received his bachelor’s degree and master’s degree in Physiology from Nanjing
University, China. He received his PhD in Cancer Biology from University of Arizona,
He is a member of China National “Thousand Talent Program”.